Recent data has highlighted a concerning trend for ‘reoffending’ drug-drive cases across England and Wales.
The data, obtained by the Ministry of Justice via a Freedom of Information request, shows that almost half of ALL recorded drug-driving offences are from those who have offended before.
There were 3,193 instances of drug-drive reoffending in 2024, more than double the 1,363 recorded in 2020, which represents a 134% increase in just four years, underlining how repeat offending has become a growing challenge for road safety enforcement.
In fact, 44% of all drug-driving offences are committed by reoffenders, which has prompted calls from road safety campaigners for a review over whether the current penalties and processes for drug-driving are fit for purpose.
How Is Drug-Driving Detected?
When officers suspect drug-driving, roadside screening tests are typically used to detect substances such as cannabis and cocaine.
Those tests are often supported by a ‘Field Impairment Test’ (FIT) which involves drivers completing physical tasks to assess coordination and balance.
If a driver fails these checks, or if impairment is still suspected, they are arrested and required to provide a blood or urine sample at a police station. These samples are then sent for laboratory analysis, which can take up to six months to process.
And it’s that six month delay that many campaigners are arguing is a big part of the problem, with offenders often allowed to continue to get behind the wheel while they await the results of their tests.
In some cases, offenders have even caused fatal collisions during this ‘delay’ period.
High-profile cases have intensified calls for reform, with victims killed by drivers who were already on bail for drug-driving while test results were pending.
The issue has been acknowledged in the Government’s new road safety strategy, which proposes temporary licence suspension powers for police where drivers test positive at the roadside.
Could Drug Driving Policies Change To Improve Road Safety?
The government is being urged to look to the blueprint provided by other countries around drug-driving policies, with countries such as Australia adopting evidential roadside saliva testing that reduces the delay.
That’s been in place for almost two decades and allows cases to be processed quicker, as well as giving laboratory confirmation without the need for months of limbo.
Interesting, a recent survey indicated that 82% of drivers support an immediate licence suspension for anyone who test positive for drugs at the roadside, while they await the laboratory results.
The broader trend is equally concerning, too…
In 2024, 20,072 people were sentenced for drug-driving offences, a figure 143% higher than in 2017, showing that drug-driving is rising as an overall picture, not just among repeat offenders.
A drug-driving conviction currently carries a minimum one-year driving ban, an unlimited fine, and up to six months in prison. Unlike drink-driving, however, there is currently no national rehabilitation scheme for drug-drive offenders, despite evidence that rehabilitation programmes significantly reduce reoffending.
For fleets and employers, the figures reinforce the importance of clear drug and alcohol policies, proactive driver education, and ongoing monitoring. With enforcement powers likely to strengthen, the risk landscape for organisations with at-work drivers continues to evolve.
